Literature DB >> 23149592

[Daptomycin for the treatment of gram-positive infections after cardiac surgery].

B Luchting1, F Weis, J Heyn, A Beiras-Fernandez.   

Abstract

BACKGROUND AND
METHOD: Surgical infection remains a main cause of death after heart surgery, despite advances in pharmacological therapy. Daptomycin is a cyclic lipopeptide antibiotic, useful in gram-positive organisms resistant to standard treatment, including vancomycin. The aim of this study was to describe the use of daptomycin regarding efficacy, efficiency and safety in patients with gram-positive infections after heart surgery using a retrospective analysis on 49 adult patients.
CONCLUSION: Daptomycin shows excellent in vitro and in vivo activity against gram-positive organisms, such as Enterococcus faecalis, Enterococcus faecium, Staphylococcus aureus, especially MRSA. Daptomycin is also effective against increasing vancomycin-resistant or vancomycin-intermediate S. aureus.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23149592     DOI: 10.1007/s00063-012-0163-5

Source DB:  PubMed          Journal:  Med Klin Intensivmed Notfmed        ISSN: 2193-6218            Impact factor:   0.840


  28 in total

Review 1.  Antimicrobial resistance in Europe and its potential impact on empirical therapy.

Authors:  G M Rossolini; E Mantengoli
Journal:  Clin Microbiol Infect       Date:  2008-12       Impact factor: 8.067

Review 2.  Sternal wound infections.

Authors:  William J Mauermann; Priya Sampathkumar; Rodney L Thompson
Journal:  Best Pract Res Clin Anaesthesiol       Date:  2008-09

3.  Mediastinitis after cardiovascular operations: a case-control study of risk factors.

Authors:  C Y Bitkover; B Gårdlund
Journal:  Ann Thorac Surg       Date:  1998-01       Impact factor: 4.330

4.  Postoperative infections after major heart surgery and prevention of ventilator-associated pneumonia: a one-day European prevalence study (ESGNI-008).

Authors:  E Bouza; J Hortal; P Muñoz; J Pascau; M J Pérez; M Hiesmayr
Journal:  J Hosp Infect       Date:  2006-08-22       Impact factor: 3.926

5.  Infections following major heart surgery in European intensive care units: there is room for improvement (ESGNI 007 Study).

Authors:  E Bouza; J Hortal; P Muñoz; M J Pérez; M J Riesgo; M Hiesmayr
Journal:  J Hosp Infect       Date:  2006-06-15       Impact factor: 3.926

Review 6.  Daptomycin for treatment of patients with bone and joint infections: a systematic review of the clinical evidence.

Authors:  Matthew E Falagas; Konstantina P Giannopoulou; Fotinie Ntziora; Panayiotis J Papagelopoulos
Journal:  Int J Antimicrob Agents       Date:  2007-04-24       Impact factor: 5.283

7.  Risk and outcome analysis of renal replacement therapies in patients after cardiac surgery with pre-operatively normal renal function.

Authors:  D Hauer; E Kilger; I Kaufmann; S Kreth; A Beiras-Fernandez; J Briegel; G Schelling; M Schmidt; F Weis
Journal:  Anaesthesia       Date:  2009-06       Impact factor: 6.955

8.  The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections.

Authors:  Robert D Arbeit; Dennis Maki; Francis P Tally; Edward Campanaro; Barry I Eisenstein
Journal:  Clin Infect Dis       Date:  2004-05-20       Impact factor: 9.079

9.  Update of the in vitro activity of daptomycin tested against 6710 Gram-positive cocci isolated in North America (2006).

Authors:  Mariana Castanheira; Ronald N Jones; Hélio S Sader
Journal:  Diagn Microbiol Infect Dis       Date:  2008-03-07       Impact factor: 2.803

10.  Daptomycin therapy for invasive Gram-positive bacterial infections in children.

Authors:  Monica I Ardura; Asunción Mejías; Kathy S Katz; Paula Revell; George H McCracken; Pablo J Sánchez
Journal:  Pediatr Infect Dis J       Date:  2007-12       Impact factor: 2.129

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.